A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire
Metastatic Castrate-resistant Prostate (CRPC) Cancer
DRUG: ODM-201|DRUG: Enzalutamide
Patient preference, Patient preference (assessed by a single question) between ODM-201 and enzalutamide after completion of the second period of treatment., up to 24 months
To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire